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Noradrenergic neurotransmission has been associated with the modulation of higher cognitive functions mediated by the prefrontal
cortex. In the present study, the impact of noradrenergic stimulation on the human action-monitoring system, as indexed by event-
related brain potentials, was examined. After the administration of a placebo or the selective 2-adrenoceptor antagonist yohimbine,
which stimulates firing in the locus ceruleus and noradrenaline release, electroencephalograpic recordings were obtained from healthy
volunteers performing a letter flanker task. Yohimbine led to an increase in the amplitude of the error-related negativity in conjunction
with a significant reduction of action errors. Reaction times were unchanged, and the drug did not modify the N2 in congruent versus
incongruent trials, a measure of preresponse conflict, or posterror adjustments as measured by posterror slowing of reaction time. The
present findings suggest that the locus ceruleus–noradrenaline system exerts a rather specific effect on human action monitoring.
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Introduction
Noradrenergic neurotransmission has been associated with the
regulation of various cognitive processes, including vigilance, at-
tention, working memory, and executive function (Berridge and
Waterhouse, 2003). Optimal function of the prefrontal cortex has
been postulated to depend on adequate noradrenaline release
(Arnsten, 1998). Studies in monkeys have demonstrated the in-
volvement of the locus ceruleus–noradrenaline system in execu-
tive tasks (Usher et al., 1999), in which adequate noradrenergic
tone leads to improvements of performance in goal-directed be-
haviors (Aston-Jones et al., 2000). In humans, guanfacine, an
adrenergic agonist acting predominantly at postsynaptic recep-
tors at the prefrontal cortex, improves planning and spatial work-
ing memory (Jakala et al., 1999). This compound also decreases
omission and commission errors in children with attention-
deficit hyperactivity disorder (Scahill et al., 2001), thus hinting at
enhanced action monitoring in these patients.
The human action-monitoring system has been the subject of
intensive research using both functional neuroimaging measures
(Ullsperger and von Cramon, 2001; Kerns et al., 2004) and elec-
trophysiological measures (Gehring et al., 1993; Falkenstein et al.,
1995; Vidal et al., 2000; Rodrı´guez-Fornells et al., 2002). Regard-
ing the latter, the discovery of the error-related negativity (ERN),
a component of the event-related potential that is obtained in
response-locked averages with a peak at 60 –100 ms after an
erroneous response, and a frontocentral maximum has been im-
portant. The ERN has been interpreted as a correlate of the error-
detection process (Holroyd and Coles, 2002) or as a reflection of
response conflict arising because of the simultaneous activation
of the correct and incorrect response (Cohen et al., 2000; Botvin-
ick et al., 2001). Dipole source modeling (Dehaene et al., 1994;
Luu and Tucker, 2001) suggests neural generators in the anterior
cingulate cortex (ACC) and/or adjacent structures.
An important theoretical proposal views the ERN in the con-
text of reinforcement learning and attributes the ERN to phasic
changes in firing of dopaminergic projections from the mesen-
cephalon to the ACC (Holroyd and Coles, 2002). Specifically, a
phasic inhibition of firing is thought to occur when an error is
committed leading to a disinhibition of ACC neurons giving rise
to the ERN. When the basal ganglia predict that ongoing events
are “worse than expected,” they produce a negative error signal,
whereas predictions that ongoing events are “better than ex-
pected” lead to a positive error signal (Barto, 1995; Houk et al.,
1995; Montague et al., 1996). It is these negative and positive
error signals that lead to the phasic decreases and increases in the
tonic activity of the mesencephalic dopamine system. The dopa-
mine signals to the ACC are used to optimize its filtering
function.
In addition to dopaminergic input, noradrenergic fibers stem-
ming from the locus ceruleus also project to the ACC, providing
an alternative and/or complementary source of modulation for
this region (Berger, 1992). In the present study, we evaluated the
effects of the selective 2–adrenoceptor antagonist yohimbine, a
drug that increases firing in the locus ceruleus (Ivanov and
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Aston-Jones, 1995) and noradrenaline release at the synapse
(Starke et al., 1989) by blocking the autoreceptor-regulated
negative-feedback loop (Langer, 1997).
Materials andMethods
Subjects. Fifteen right-handed volunteers (seven men, eight women) with
a mean of 24.8 years of age (range, 20 –37) participated in the study.
Medical history, laboratory tests, electrocardiogram, and urinalysis were
normal, and no medication or illicit drugs were allowed 2 weeks before
the study. Subjects also abstained from alcohol, tobacco, and caffeinated
drinks for 48 h before each experimental day. The study was conducted in
accordance with the Declarations of Helsinki and Tokyo and was ap-
proved by the Hospital Ethics Committee and the Spanish Ministry of
Health.
Study design. Oral doses of 30 mg of yohimbine and placebo (lactose)
packaged in identical capsules were administered in a balanced order
according to a double-blind randomized within-subjects design. The two
experimental days were separated by at least 1 week washout period.
After arrival in the laboratory under fasting conditions, a urine sample
was obtained to test for illicit drug intake, electrodes were applied to the
scalp, and medication was given. During each recording session, volun-
teers remained in a quiet room and were asked to stay alert throughout
the experiment. The current experiment was conducted 2 h after drug
administration.
Stimuli and procedure. The Eriksen flanker task (Eriksen and Eriksen,
1974) was used, which requires a response to the center letter of a five-
letter array with either a left-hand (letter H) or right-hand (letter S)
response. Additional letters flanking the target letter either favored the
target response (congruent trials, HHHHH or SSSSS) or primed
the other response (incongruent trials, HHSHH or SSHSS). To increase
the number of errors produced, 60% of the trials were incongruent. Each
stimulus array subtended 2.5° of visual angle in width, and a fixation
cross was presented in the middle of the computer monitor just below the
target letter in the array. The duration of the stimuli was 100 ms, and a
random stimulus onset asynchrony between 900 and 1100 ms was used.
Letter/hand assignments were counterbalanced between subjects and
maintained in both sessions. Before the first experimental session, sub-
jects were trained with 200 trials to reach a reaction time (RT) baseline
level, and they were given feedback about their performance. The goal of
this procedure was to aim for a reaction time that would yield10 –15%
of errors. The experiment proper consisted of six blocks of 4 min and 200
stimuli each. A 30 s rest period was allowed between blocks. Subjects were
required to respond to the stimuli as fast as possible and to correct their
errors as fast as possible whenever they detected them.
Electrophysiological recording. The electroencephalogram was re-
corded from the scalp using gold electrodes located at 29 standard posi-
tions (Fp1/2, F3/4, C3/4, T3/4, T5/6, P3/4, O1/2, F7/8, Fz, Cz, Pz, Fc3/4,
FT7/8, Cp3/4, TP7/8, PO3/4). Biosignals were rereferenced off-line to the
mean of the activity at the two mastoid leads. Vertical eye movements
were monitored with an electrode at the infraorbital ridge of the left eye.
Electrode impedances were kept5 k. The electrophysiological signals
were filtered with a bandpass of 0.1–50 Hz and
digitized at a rate of 250 Hz. Trials in which
base-to-peak electrooculogram amplitude was
100V, amplifier saturation occurred, or the
baseline shift was 300 V/s were automati-
cally rejected.
Response-locked event-related brain poten-
tials (ERPs) were averaged starting 400 ms be-
fore the response of the subject until 624 ms
after response onset. The baseline used for the
response-locked ERN was between 150 and
50 ms. Stimulus-locked ERPs were averaged
over epochs of 1024 ms starting 100 ms before
the stimulus. The mean amplitude value in the
interval between 100 and 0 ms was used as
baseline. Two types of trials were averaged sep-
arately: correct responses and errors. The re-
sulting ERPs were filtered with a low-pass filter
(12 Hz half-amplitude cutoff).
ERP effects were quantified for the three midline electrodes (Fz, Cz,
and Pz), and the resulting data were subjected to repeated-measures
ANOVAs with the Greenhouse–Geisser  correction applied when nec-
essary. The original degrees of freedom and corrected p values are given
in Results.
Results
Behavioral analysis
Main behavioral results are shown in Table 1. A main effect of the
type of response reflected faster reaction times for erroneous re-
sponses (correct, 327 33 ms; erroneous, 269 23 ms; F(1,14)
131; p  0.001). Congruent trials were faster than incongruent
trials (F(1,14)  77; p  0.001), although this effect was larger in
correct than in incorrect trials (type of trial  compatibility,
F(1,14) 35; p 0.001). Neither a main effect of treatment (F
1) nor treatment by type of response or treatment by compatibil-
ity (both F  1) were found. The time needed to correct an
erroneous response did not differ regarding compatibility or
treatment (F  1, in both cases; mean corrective reaction time:
placebo, 191 53 ms; yohimbine, 186 49 ms).
The same analysis was performed on the percentage of erro-
neous responses (corrected and uncorrected). This value was
higher in the incongruent condition compared with the congru-
ent condition (F(1,14) 56.9; p 0.001) (Table 1). In the yohim-
bine condition, subjects committed less erroneous responses
(F(1,14) 5.45; p 0.05). The interaction between compatibility
and treatment was not significant (F 1). Regarding the percent-
age of erroneous responses that were afterward corrected, no
significant differences were found for treatment (F 1), compat-
ibility (F(1,14) 3.3; p 0.09), or their interaction (F 1).
Posterror adjustments were measured by assessing posterror
slowing and the number of errors after erroneous responses. Re-
action times to correct trials immediately following a correct or
an erroneous response, respectively, are shown in Table 1. A two-
way ANOVA showed a main effect of type of preceding response
(correct vs erroneous; F(1,14)  12.09; p  0.01) but no effect of
treatment (F 1) and no preceding response by treatment inter-
action (F(1,14)  2.04; p  0.2). On the contrary, a marginally
significant decrease was observed in the number of errors that
followed an erroneous response (Table 1) after yohimbine ad-
ministration (F(1,14) 4.4; p 0.054).
ERP analysis
The percentage of EEG epochs rejected as a result of artifacts did
not differ between treatments (F(1,14) 1; placebo, 14%; yohim-
bine, 16%). The mean number of errors entered into the average
Table 1. Behavioral measures in each treatment condition expressed as mean (SD)
Reaction time and performance data
Placebo Yohimbine
Congruent Incongruent Congruent Incongruent
Compatibility
RT correct 316 (34) 338 (34) 314 (28) 340 (26)
RT errors 263 (28) 274 (27) 266 (21) 275 (15)
Percentage of errors 13.1 (4.7) 26.8 (9.4) 10.6 (5.2) 23.7 (7.9)
Percentage of corrections 92.7 (7.8) 94.4 (5.8) 93.7 (6.9) 95.05 (4.2)
Posterror adjustments
RT after correct 325 (39) 323 (27)
RT after error 340 (41) 344 (38)
n errors after errors 42 (30) 32 (28)
RTs are expressed in milliseconds.
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after artifact rejection was 227  72 for
placebo and 207  72 for yohimbine
(F(1,14) 2.75; p 0.10).
The response-locked averages are de-
picted in Figure 1A. Although no medica-
tion differences are apparent for the cor-
rect trials, the ERN component in the error
trials was increased in the yohimbine con-
dition. A mean amplitude measure in the
time window of 0 –100 ms (Fz, Cz, and Pz)
yielded a main effect of type of response
(F(1,14) 71.1; p 0.001). Although there
was no main effect of treatment (F(1,14)
3.7; p 0.07), a significant interaction be-
tween type of response and treatment
(F(1,14)  8.27; p  0.012) reflected the
selective effect of yohimbine on erroneous
responses.
Post hoc analyses on the error trials re-
vealed that yohimbine increased the ERN
component for both Fz (F(1,14) 4.6; p
0.05) and Cz (F(1,14)  11.2; p  0.005)
electrode sites.
To check whether the reduced error
rate observed after yohimbine accounted
for the amplitude increases in the ERN, the
difference in error rate between the yo-
himbine condition and placebo was intro-
duced as a covariate in the ANOVA. This
analysis yielded again a significant type of
response by treatment interaction at Cz
(F(1,13) 7.1; p 0.05), indicating that the
drug-induced enhancement of the ERN
persisted after controlling for differences
in performance accuracy.
A typical frontocentral distribution was
found for the ERN (Fig. 1C), and the sub-
traction (yohimbine minus placebo, error
trials) showed a similar distribution, indi-
cating that the effect of yohimbine was on
the ERN component.
To test for treatment effects on the er-
ror positivity (Pe) (i.e., the positive com-
ponent that follows the ERN) (Fig. 1A), we computed the peak
amplitude for this component at Pz in the erroneous trials (time
window, 100 – 400 ms). No significant differences were found
between placebo and yohimbine either in amplitude (F 1; pla-
cebo, 5.4  2.7 V; yohimbine, 5.1  2.7 V) or in latency for
this component (F 1; placebo, 190 66 ms; yohimbine, 189
56 ms).
Stimulus-locked ERPs
The stimulus-locked averages (Fig. 1B) showed no major differ-
ences resulting from treatment for the early ERP components
(N1 or P2). At 250 ms, a negative component (N2) was ob-
served, which was somewhat broader in the erroneous trials. The
N2 was quantified by a mean amplitude measure (250 – 450 ms).
Errors showed an increased negativity when compared with cor-
rect responses (type of response, F(1,14) 28.8; p 0.001). Treat-
ment (F(1,14) 1.8; p 0.13) and the interaction between type of
response and treatment were not significant (F(1,14)  2.9; p 
0.10). However, a significant interaction between treatment and
type of response and electrode was found (F(2,28)  5.18; p 
0.012). Pairwise comparisons of the error trials revealed that yo-
himbine increased negativity mainly at Cz (F(1,14)  6.8; p 
0.020).
Previous studies have found a larger N2 in incongruent com-
pared with congruent trials (Van Veen and Carter, 2002). This
was also found in the present study (Fig. 2). An ANOVA was
performed on a mean amplitude measure (250 –350 ms time win-
dow) for correct trials at midline locations, with compatibility
and treatment as within-subject factors. As expected, incongru-
ent trials (Fig. 2A) showed an increase in the frontal N2 compo-
nent compared with congruent trials. This effect was significant
(F(1,14) 28.9; p 0.001; congruent, 4.3 4.3V; incongruent,
2.5 4.2V). Neither treatment (F(1,14) 1) nor the interaction
between treatment and compatibility (F(1,14)  1) showed any
significant effect.
To confirm the lack of an effect of yohimbine on the N2 am-
plitude difference in incongruent versus congruent correct trials,
the incongruent– congruent difference waves were obtained
(Fig. 2B), and the peak values in the 250 – 450 ms time range
were submitted to statistical analysis. Again, repeated-measures
Figure 1. A, Response-locked ERPs depicted for correct and erroneous responses in each treatment condition (placebo and
yohimbine). Note the increased negativity just after the commission of the errors (ERN component) and the larger ERN observed
after yohimbine.B, Stimulus-lockedERPs showabroad increase innegativity in the yohimbine condition, just after thepeakof the
N2 component,which is followedby a reduced central positivity superimposed over the P3 component. C, Topographicalmaps for
the ERN component in both treatment conditions using isovoltage spline interpolation for the 50–100 ms interval. Relative
scaling was used. Minimum and maximum values for each isovoltage map are as follows: placebo,3.29/1.9V; yohimbine,
4.9/1.68V; yohimbine minus placebo,1.69/0.08V.
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ANOVAs with treatment as a factor did not show any significant
peak amplitude differences either at Fz, (F(1,14) 1.6; p 0.2) or
at Cz (F(1,14) 1).
The stimulus-locked averages suggest that there is no medica-
tion effect on the P3 component. Indeed, a peak amplitude mea-
sure (time window, 200 – 600 ms; Pz electrode) revealed no main
effect of type of response or treatment. Also, the interaction of
type of response and treatment was nonsignificant (all F 1). A
P3 peak latency measure (same time window) demonstrated a
delay for erroneous trials (F(1,14)  41.3; p  0.001; correct
responses, 372 38 ms; erroneous, 425 64 ms). There were
no treatment effects on P3 latency, however, and the interac-
tion between treatment and type of response was nonsignifi-
cant (both F  1).
Discussion
Noradrenergic stimulation appears to selectively enhance elec-
trophysiological correlates of action monitoring in humans. The
selective 2–adrenoceptor antagonist yohimbine decreased the
number of action errors in the Eriksen flanker task and increased
the amplitude of the ERN. No effects were observed on reaction
times, posterror slowing, or other components of the ERP. Spe-
cifically, the amplitude difference of the N2 component of the
stimulus-locked ERPs in the congruent versus incongruent cor-
rect responses, which has been interpreted as an indicator of
response conflict, was not modified by yohimbine. These find-
ings are the first to demonstrate the facilitatory effects of in-
creased noradrenergic activity on the human error-monitoring
system. Previous studies with different paradigms did not reveal
robust effects of yohimbine on ERPs. For example, in a choice
reaction time task, it modified neither the reaction times nor the
latencies and amplitudes of the N200 and the P3 components of
the visual ERP (Halliday et al., 1994). In another study involving
a three-tone target detection task, yohimbine did not modify the
latency of the N250 or the P3b associated with target identifica-
tion and reaction times (Turetsky and Fein, 2002). However, a
trend toward an increase in performance accuracy was observed.
Interestingly, the drug did modify the orienting response to novel
or rare stimuli, speeding P3a peak latency and increasing its am-
plitude. Thus, yohimbine appeared to modify activity of the fron-
tal attentional network, which, like the error-monitoring system,
is thought to be subserved by the ACC (Posner and Petersen,
1990).
Previously, drug effects on the ERN as an indicator of the
human action-monitoring system have been interpreted in the
light of the reinforcement-learning theory (Holroyd and Coles,
2002), which attributes the ERN to phasic changes in firing of the
mesencephalon-ACC dopaminergic pathways. Pharmacological
investigations have in fact demonstrated a modulatory role of the
dopamine system in the generation of the ERN. De Bruijn et al.
(2004) observed an enlargement of the ERN and no effect on
reaction time or error rates after administration of 15 mg of
amphetamine, an indirect dopamine agonist, whereas the dopa-
minergic antagonist haloperidol (3 mg; single dose) has been
found to attenuate the ERN (Zirnheld et al., 2004). Finally, caf-
feine (3 or 5 mg/kg body weight), an adenosine receptor antago-
nist influencing dopaminergic neurotransmission, yielded larger
ERNs together with reductions in reaction times and error rates
(Tieges et al., 2004).
The present findings show that in addition to the dopamine
system, the noradrenergic system might serve as a complemen-
tary source of modulation of the ERN. Noradrenergic neuro-
transmission does not seem to be involved in reward. Rather, the
locus ceruleus–noradrenaline system appears to modulate infor-
mation processing by increasing the signal-to-noise ratio of rele-
vant information (Servan-Schreiber et al., 1990). The activity of
this system seems to depend on the salience of the stimulus and to
be independent of its emotional valence (for review, see Berridge
and Waterhouse, 2003). Thus, even if changes in noradrenergic
firing do not constitute the central event generating the ERN, it is
plausible that increased noradrenergic neurotransmission leads
to a facilitation of activity in the ACC. It is worth mentioning that
in the present study, we observed a dissociation of yohimbine
effects on the N2 congruency effect and on the ERN. A possible
explanation is that the locus ceruleus–noradrenergic system is
differently engaged in each situation, in line with a proposed
synchronization of activity in the ACC mediated by phasic dis-
charges of the locus ceruleus (Paus, 2001). Additionally, there
exists evidence from neuroimaging studies indicating that (pre-)
response conflict and error processing may be mediated by dif-
ferent anatomical substrates within the frontomedial cortex (Ull-
sperger and von Cramon, 2001).
An alternative explanation to the effects of yohimbine on the
ERN is that increased noradrenergic tone could enhance the ac-
tivity of other neural systems in addition to the ACC, thus facil-
itating stimulus detection and stimulus-response mapping or in-
creasing salience of the error. Although our current results are
rather selective for the ERN, our data do not allow us to attribute
the effects of yohimbine exclusively to specific increases in acti-
vation of the ACC. Other brain areas, such as the lateral prefron-
tal cortex, interact with the ACC to modulate the ERN (Gehring
and Knight, 2000). Activation at this level could have played a
role in the present findings. Additionally, it is possible that
yohimbine-induced increases in selective attention could have
led to the observed enhancement of the ERN. Other studies have
Figure 2. A, Stimulus-locked ERPs for congruent and incongruent trials at Fz and Cz, show-
ing an increase in the amplitude of the N2 component in the incongruent trials.B, Incongruent
minus congruent difference waves at Fz and Cz for the placebo and yohimbine conditions. The
congruency effect on the N2 was not modified by yohimbine administration.
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shown that decreasing attention has a negative impact on ERN
amplitude (Pailing and Segalowitz, 2004).
In conclusion, the stimulation of noradrenergic neurotrans-
mission enhanced the ERN and improved performance accuracy
in the absence of additional effects on other ERP components or
reaction times. The present findings suggest that the locus cerule-
us–noradrenaline system exerts a modulatory activity on action
monitoring in humans. Future research should identify the sub-
processes and neural substrates targeted by, and assess the inter-
play between, dopaminergic and noradrenergic neurotransmis-
sion in the genesis and modulation of the ERN.
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